Scrutiny in store for EU conditional authorization pathway flaws
This article was originally published in SRA
Executive Summary
A new European Commission expert group is scheduled to discuss today the flaws in the EU conditional marketing authorization pathway. The pathway is one of several tools aimed at bringing important new medicines to market faster, but it has been criticized for failing to fully achieve its intended aims1-3.